Anti-VEGF antibodies and their uses

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9815893
SERIAL NO

14648385

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ABBVIE BIOTHERAPEUTICS INC1 N WAUKEGAN ROAD NORTH CHICAGO IL 60064

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Akamatsu, Yoshiko Palo Alto, US 21 172

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 14, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 14, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00